1.Molecular association of CD98, CD29, and CD147 critically mediates monocytic U937 cell adhesion.
The Korean Journal of Physiology and Pharmacology 2016;20(5):515-523
Adhesion events of monocytes represent an important step in inflammatory responses induced by chemokines. The β1-integrin CD29 is a major adhesion molecule regulating leukocyte migration and extravasation. Although several adhesion molecules have been known as regulators of CD29, the molecular interactions between CD29 and its regulatory adhesion molecules (such as CD98 and CD147) have not been fully elucidated. Therefore, in this study, we examined whether these molecules are functionally, biochemically, and cell-biologically associated using monocytic U937 cells treated with aggregation-stimulating and blocking antibodies, as well as enzyme inhibitors. The surface levels of CD29, CD98, and CD147 (but not CD43, CD44, and CD82) were increased. The activation of CD29, CD98, and CD147 by ligation of them with aggregation-activating antibodies triggered the induction of cell-cell adhesion, and sensitivity to various enzyme inhibitors and aggregation-blocking antibodies was similar for CD29-, CD98-, and CD147-induced U937 cell aggregation. Molecular association between these molecules and the actin cytoskeleton was confirmed by confocal microscopy and immunoprecipitation. These results strongly suggest that CD29 might be modulated by its biochemical and cellular regulators, including CD98 and CD147, via the actin cytoskeleton.
Actin Cytoskeleton
;
Antibodies
;
Antibodies, Blocking
;
Chemokines
;
Enzyme Inhibitors
;
Immunoprecipitation
;
Leukocytes
;
Ligation
;
Microscopy, Confocal
;
Monocytes
;
U937 Cells*
2.Recent Updates in Cancer Immunotherapy.
Korean Journal of Otolaryngology - Head and Neck Surgery 2015;58(7):449-455
Immune system is believed to play an important role in cancer initiation as well as its progression, as evidenced by many studies revealing suppressed, defective anti-tumor immunity in cancer patients. Modulating various components in immune surveillance, such as cytokine, antigen-presenting cells, or B/T lymphocytes, to control and eradicate cancer has been an attractive theme, however, preclinical/clinical trials have not been successful enough to introduce immunotherapy into practice. Recently, enthusiasm on cancer immunotherapy has been revived mostly due to 1) growing body of data on the mechanism of immune checkpoint in cancer, and 2) promising studies performed in advanced, solid cancer patients treated with blocking antibodies targeting cytotoxic T lymphocyte-associated antigen-4 or programmed cell death protein-1 pathways. The immune checkpoints blockade is likely to be a novel armament in cancer management as the outcomes of ongoing clinical trials are released in future.
Antibodies, Blocking
;
Antigen-Presenting Cells
;
Cell Death
;
Humans
;
Immune System
;
Immunotherapy*
;
Lymphocytes
3.Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy.
Jae Hun SHIN ; Hyung Bae PARK ; Kyungho CHOI
Immune Network 2016;16(2):134-139
Programmed death-1 (PD-1) is a strong negative regulator of T lymphocytes in tumor-microenvironment. By engaging PD-1 ligand (PD-L1) on tumor cells, PD-1 on T cell surface inhibits anti-tumor reactivity of tumor-infiltrating T cells. Systemic blockade of PD-1 function using blocking antibodies has shown significant therapeutic efficacy in clinical trials. However, approximately 10 to 15% of treated patients exhibited serious autoimmune responses due to the activation of self-reactive lymphocytes. To achieve selective activation of tumor-specific T cells, we generated T cells expressing a dominant-negative deletion mutant of PD-1 (PD-1 decoy) via retroviral transduction. PD-1 decoy increased IFN-γ secretion of antigen-specific T cells in response to tumor cells expressing the cognate antigen. Adoptive transfer of PD-1 decoy-expressing T cells into tumor-bearing mice potentiated T cell-mediated tumor regression. Thus, T cell-specific blockade of PD-1 could be a useful strategy for enhancing both efficacy and safety of anti-tumor T cell therapy.
Adoptive Transfer
;
Animals
;
Antibodies, Blocking
;
Autoimmunity
;
Cell- and Tissue-Based Therapy
;
Humans
;
Lymphocytes
;
Mice
;
T-Lymphocytes
;
T-Lymphocytes, Cytotoxic*
;
Zidovudine
4.Immunologic Mechanism of Experimental and Therapeutic Ultraviolet B Responses.
Immune Network 2002;2(2):65-71
The immunological mechanism of the responses to ultraviolet (UV) B radiation in mouse models were investigated by the suppression of contact hypersensitivity (CHS) and delayed type hypersensitivity (DTH), and susceptibility to infection. However, there are some differences in immune suppression according to the different models as well as the irradiation protocols. Therefore, this review focused on the differences in the suppressive effects on CHS and DTH, and susceptibility to infection in relation to the different in vivo models. Recent advances in cytokine knockout mice experiments have the reexamination of the role of the critical cytokines in UVB-induced immune suppression, which was investigated previously by blocking antibodies. The characteristics of the suppressor cells responsible for UVB-induced tolerance were determined. The subcellular mechanism of UVB-induced immune suppression was also explained by the induction of apoptotic cells through the Fas and Fas-ligand interaction. The phagocytosis of the apoptotic cells is believed to induce the production of the immune suppressive cytokine like interleukin-10 by macrophages. Therefore, the therapeutic UVB response to a skin disease, such as psoriasis, by the depletion of infiltrating T cells could be considered in the extension line of apoptosis and immune suppression.
Animals
;
Antibodies, Blocking
;
Apoptosis
;
Cytokines
;
Dermatitis, Contact
;
Hypersensitivity
;
Interleukin-10
;
Macrophages
;
Mice
;
Mice, Knockout
;
Phagocytosis
;
Psoriasis
;
Skin Diseases
;
T-Lymphocytes
5.Regulatory Mechanism of p66 Shc Expression by TSH in FRTL-5 Cells.
Young Joo PARK ; Eun Shin PARK ; Tae Yong KIM ; Yun Yong LEE ; Seon Hwa LEE ; Do Joon PARK ; Chan Soo SHIN ; Kyoung Soo PARK ; Seong Yeon KIM ; Hong Kyu LEE ; Bo Youn CHO
Journal of Korean Society of Endocrinology 2003;18(1):45-55
BACKGROUND: Thyroid goiters are very common, however, the mechanism of development is not fully understood. A TSH receptor has been known to activate two different signaling pathways the cAMP/protein kinase A(PKA) and phospholipase C(PLC)/protein kinase C(PKC) systems. However, both systems are limited in the degree to which they explain the discrepancy between a goiter and TSH receptor activation. It has recently been reported that the expression of p66 Shc was increased by TSH stimulation in thyrocytes, suggesting that the p66 Shc molecule may play a critical role in the transition of the TSH-induced growth signals. METHODS AND RESULTS: In this study, we examined the expression of p66 Shc by stimulation of TSH, and the regulatory mechanisms of the TSH-induced expression of the p66 Shc in FRTL-5 cells. In FRTL-5 cells, TSH could increase the expression of the p66 Shc, and the this expression was decreased to basal levels after the removal of TSH. The TSH-induced p66 Shc expression was competitively inhibited by TSH receptor blocking antibodies. The increments of the expression of the p66 Shc protein caused by TSH were both time and concentration dependent, and it was same in the mRNA levels. Cholera toxin increased the expression of the p66 Shc, while pertussis toxin did not. The activators of the cAMP/PKA pathway (8-bromo-cAMP and forskolin) also stimulated the expression of p66 Shc, and the PKA inhibitor H89 decreased the expression, while the inhibition of the PKC pathway by GF109203X, or PMA, affected the expression of p66 Shc very little. CONCLUSION: Our data suggests that p66 Shc may play an important role in regulating the growth of thyrocytes. The TSH receptor - Gs protein - adenylate cyclase - cAMP - PKA pathway mainly mediates the TSH effects on the expression of p66 Shc molecules.
Adenylyl Cyclases
;
Antibodies, Blocking
;
Cholera Toxin
;
Goiter
;
Pertussis Toxin
;
Phospholipases
;
Phosphotransferases
;
Receptors, Thyrotropin
;
RNA, Messenger
;
Thyroid Gland
6.Simultaneous Inhibition of CXCR4 and VLA-4 Exhibits Combinatorial Effect in Overcoming Stroma-Mediated Chemotherapy Resistance in Mantle Cell Lymphoma Cells.
Immune Network 2014;14(6):296-306
There is growing evidence that crosstalk between mantle cell lymphoma (MCL) cells and stromal microenvironments, such as bone marrow and secondary lymphoid tissues, promotes tumor progression by enhancing survival and growth as well as drug resistance of MCL cells. Recent advances in the understanding of lymphoma microenvironment have led to the identification of crucial factors involved in the crosstalk and subsequent generation of their targeted agents. In the present study, we evaluated the combinatory effect of blocking antibodies (Ab) targeting CXCR4 and VLA-4, both of which were known to play significant roles in the induction of environment-mediated drug resistance (EMDR) in MCL cell line, Jeko-1. Simultaneous treatment with anti-CXCR4 and anti-VLA-4 Ab not only reduced the migration of Jeko-1 cells into the protective stromal cells, but also enhanced sensitivity of Jeko-1 to a chemotherapeutic agent to a greater degree than with either Ab alone. These combinatorial effects were associated with decreased phosphorylation of ERK1/2, AKT and NF-kappaB. Importantly, drug resistance could not be overcome once the adhesion of Jeko-1 to the stromal occurred despite the combined use of Abs, suggesting that the efforts to mitigate migration of MCLs should be attempted as much as possible. Our results provide a basis for a future development of therapeutic strategies targeting both CXCR4 and VLA-4, such as Ab combinations or bispecific antibodies, to improve treatment outcomes of MCL with grave prognosis.
Antibodies, Bispecific
;
Antibodies, Blocking
;
Bone Marrow
;
Cell Line
;
Drug Resistance
;
Drug Therapy*
;
Integrin alpha4beta1*
;
Lymphoid Tissue
;
Lymphoma
;
Lymphoma, Mantle-Cell*
;
NF-kappa B
;
Phosphorylation
;
Prognosis
;
Stromal Cells
7.Graves' Disease: Can It Be Cured?
Endocrinology and Metabolism 2019;34(1):29-38
Whether or not Graves' hyperthyroidism can be really cured, depends on the definition of “cure.” If eradication of thyroid hormone excess suffices for the label “cure,” then all patients can be cured because total thyroidectomy or high doses of 1¹³¹I will abolish hyperthyroidism albeit at the expense of creating another disease (hypothyroidism) requiring lifelong medication with levothyroxine. I would not call this a “cure,” which I would like to define as a state with stable thyroid stimulating hormone (TSH), free thyroxine, and triiodothyronine serum concentrations in the normal range in the absence of any thyroid medication. Surgery and radioiodine are unlikely to result in so-defined cures, as their preferable aim as stated in guidelines is to cause permanent hypothyroidism. Discontinuation of antithyroid drugs is followed by 50% recurrences within 4 years; before starting therapy the risk of recurrences can be estimated with the Graves' Recurrent Events After Therapy (GREAT) score. At 20-year follow-up about 62% had developed recurrent hyperthyroidism, 8% had subclinical hypothyroidism, and 3% overt hypothyroidism related to TSH receptor blocking antibodies and thyroid peroxidase antibodies. Only 27% was in remission, and might be considered cured. If the definition of “cure” would also include the disappearance of thyroid antibodies in serum, the proportion of cured patients would become even lower.
Antibodies
;
Antibodies, Blocking
;
Antithyroid Agents
;
Follow-Up Studies
;
Graves Disease
;
Humans
;
Hyperthyroidism
;
Hypothyroidism
;
Iodide Peroxidase
;
Receptors, Thyrotropin
;
Recurrence
;
Reference Values
;
Thyroid Gland
;
Thyroidectomy
;
Thyrotropin
;
Thyroxine
;
Triiodothyronine
8.A Case of Transient Neonatal Hypothyroidism Due to Maternal TSH-Binding Inhibitor Immunoglobulins.
Shung Shin KIM ; Moon Young SONG ; Byung Kyu SHU ; Byung Churl LEE
Journal of Korean Society of Pediatric Endocrinology 1998;3(1):84-89
Recognition of transient forms of neonatal hypothyroidism is very important to prevent the complications of congenital hypothyroidism. Transplacental passage of TSH-binding inhibitory immunoglobulins(TBII) may result in transient congenital hypothyroidism. Transient neonatal hypothyroidism was found in a daughter of 25-yr-old mother who was receiving levothyroxine for primary hypothyroidism due to Hashimoto's thyroiditis. The neonate was treated with thyroxine which was discontinued at 24 months of age. Thyroid scanning during the neonatal period failed to identify functional thyroid tissue, suggesting thyroid agenesis, whereas thyroid scan performed on subsequent follow-up revealed a normal gland. Sequential measurements of serum autoantibodies directed towards the TSH receptor were made in the patient and her mother. High titers of blocking antibodies were present in the mother(TBII, 82.1%) and newborn(TBII, 85.5%) at 19 days after birth. The levels remained persistently high in the mother, whereas they declined and undetectable in the patient at 23 months of age. The above laboratory and clinical data were compatible with blocking nature of TBII, resulting in transient neonatal hypothyroidism and an athyreotic appearance on scan. The TBII measurement can be a useful predictor of neonatal hypothyroidism as well as confirming the nature of the disease in newborn.
Antibodies, Blocking
;
Autoantibodies
;
Congenital Hypothyroidism
;
Follow-Up Studies
;
Humans
;
Hypothyroidism*
;
Immunoglobulins*
;
Infant, Newborn
;
Mothers
;
Nuclear Family
;
Parturition
;
Receptors, Thyrotropin
;
Thyroid Dysgenesis
;
Thyroid Gland
;
Thyroiditis
;
Thyroxine
9.Thrombospondin-1 and Inhibition of Tumor Growth.
Korean Journal of Physical Anthropology 2015;28(4):175-184
Thrmobospondin-1 is the multifunctional protein that modulates endothelial cell and tumor cell behavior via several cell surface receptors and inhibits angiogenesis. In vitro, thrombospondin-1 alters adhesion, proliferation, motility, and survival of endothelial and cancer cells. Studies have confirmed that increased TSP-1 expression suppresses growth or metastasis of some tumors and inhibits angiogenesis. In the past three decades, inhibitors of angiogenesis have been developed as regulators target the vascular endothelial growth factor (VEGF) signaling pathway and small molecule tyrosine kinase inhibitors have been clinically approved. TSP-1 has several functional domain structures and inhibits tumor angiogenesis by engaging receptors CD36 and CD47. TSP-1 binding to CD47 dissociates it from VEGFR2, inhibiting downstream AKT activation and functional responses of endothelial cells to VEGF. Recently, macrophage phagocytosis and cytotoxic T-cell induction of tumor cells mediated by CD47-specific blocking antibodies have been proposed. These findings provide a new therapeutic paradigm for elinination of cancer cells and inhibition of angiogenesis of tumor by TSP-1.
Antibodies, Blocking
;
Endothelial Cells
;
Macrophages
;
Neoplasm Metastasis
;
Phagocytosis
;
Protein-Tyrosine Kinases
;
Receptors, Cell Surface
;
T-Lymphocytes
;
Thrombospondin 1
;
Vascular Endothelial Growth Factor A
10.Successful anesthetic management of two myasthenic patients using total intravenous anesthesia without muscle relaxants: A report of two cases.
Jong Taek PARK ; Si gon KIM ; Young bok LEE
Anesthesia and Pain Medicine 2011;6(4):385-388
Myasthenia gravis (MG) is an autoimmune-mediated disease characterized by weakness and fatigability due to dysfunction of the neuromuscular junction from antibodies directed against the acetylcholine receptor (AchR). The main considerations for the anesthesiologist are the underlying muscle weakness and interactions with various anesthetic drugs. This includes sensitivity to neuromuscular blocking agents and volatile agents, and the risk of postoperative respiratory failure. We report two cases of transsternal thymectomy for MG under general anesthesia with the use of a bispectral index-monitored total intravenous technique using propofol and remifentanil without muscle relaxants.
Acetylcholine
;
Anesthesia, General
;
Anesthesia, Intravenous
;
Anesthetics
;
Antibodies
;
Humans
;
Muscle Weakness
;
Muscles
;
Myasthenia Gravis
;
Neuromuscular Blocking Agents
;
Neuromuscular Junction
;
Piperidines
;
Propofol
;
Respiratory Insufficiency
;
Thymectomy